Taysha Gene Therapies Inc. (TSHA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taysha Gene Therapies Inc. (TSHA:NASDAQ), powered by AI.

Current Price
$5.85
Sector
Healthcare
What is the Taysha Gene Therapies Inc. stock price forecast?

Taysha Gene Therapies Inc. is currently trading at $5.85. View real-time AI analysis on Alpha Lenz.

What is Taysha Gene Therapies Inc. insider trading activity?

View the latest insider trading data for Taysha Gene Therapies Inc. on Alpha Lenz.

What is Taysha Gene Therapies Inc.'s P/E ratio?

View Taysha Gene Therapies Inc.'s valuation metrics on Alpha Lenz.

Taysha Gene Therapies Inc.

NASDAQ · TSHA
$5.85-0.12(-2.01%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Taysha Gene Therapies Inc.'s future dividend policy...
Alpha Chat Insight

Taysha Gene Therapies Inc.'s ROE is -68.5%. Explore profitability and growth together.

Ask for details

Company Overview

Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.

CEOMr. Sean P. Nolan
SectorHealthcare
IndustryBiotechnology
Employees73

Company Statistics

FY 2025

Profile

N/AMarket Cap
$9.77MRevenue
0.00Shares Out
73Employees

Margins

N/AGross
-1090.64%EBITDA
-1130.65%Operating
-1115.27%Pre-Tax
-1115.27%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

57.49%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-43.28%ROA
-68.45%ROE
-43.25%ROIC

Financial Health

$319.77MCash & Cash Equivalents
$-223.38MNet Debt
39.03%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Taysha Gene Therapies Inc. (ticker: TSHA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 73 employees.

The current price is $5.85 with a P/E ratio of -x and P/B of -x.

ROE is -68.45% and operating margin is -1130.65%. Annual revenue is $10M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Taysha Gene Therapies Inc. (TSHA) Stock Forecast 2026 $5.85 — Price, Financials & Analyst Targets | Alpha Lenz